Denali Therapeutics (DNLI) Capital Leases (2024 - 2026)

Denali Therapeutics (DNLI) has 3 years of Capital Leases data on file, last reported at $5.5 million in Q1 2026.

• On a quarterly basis, Capital Leases fell 1.61% year-over-year to $5.5 million in Q1 2026; TTM through Mar 2026 was $5.5 million, a 1.61% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, down 1.48% from the prior year.
• Capital Leases for Q1 2026 stood at $5.5 million, roughly flat from $5.5 million in the prior quarter.
• Over the last five years, Capital Leases for DNLI reached as high as $5.6 million in Q3 2024 and fell as low as $5.5 million in Q1 2026.
• Historically, Capital Leases has averaged $5.6 million across 3 years, with a median of $5.6 million in 2025.
• Across the five-year window, Capital Leases slipped 1.37% in 2025 and fell 1.61% in 2026, its largest moves.
• Year by year, Capital Leases stood at $5.6 million in 2024, then fell by 1.48% to $5.5 million in 2025, then slipped by 0.43% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Capital Leases figures were $5.5 million in Q1 2026, $5.5 million in Q4 2025, and $5.6 million in Q3 2025.